vs
ANI PHARMACEUTICALS INC（ANIP）与Apple Hospitality REIT, Inc.（APLE）财务数据对比。点击上方公司名可切换其他公司
Apple Hospitality REIT, Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.4倍（$337.7M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 8.2%，领先2.9%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 3.1%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs -6.9%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
莱曼 hospitality properties是一家深耕酒店、度假村、娱乐及媒体领域的企业，得名于旗下核心资产——位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾作为爱德华·盖洛德旗下俄克拉荷马出版公司子公司的时期，1983年收购WSM公司后，拿下大奥普里等知名IP，奠定了如今的业务发展基础。
ANIP vs APLE — 直观对比
营收规模更大
APLE
是对方的1.4倍
$247.1M
营收增速更快
ANIP
高出26.6%
3.1%
净利率更高
ANIP
高出2.9%
8.2%
两年增速更快
ANIP
近两年复合增速
-6.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $337.7M |
| 净利润 | $27.5M | $27.7M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | 14.2% |
| 净利率 | 11.1% | 8.2% |
| 营收同比 | 29.6% | 3.1% |
| 净利润同比 | 367.5% | 12.7% |
| 每股收益（稀释后） | $1.14 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPAPLE
| Q1 26 | — | $337.7M | ||
| Q4 25 | $247.1M | $326.4M | ||
| Q3 25 | $227.8M | $373.9M | ||
| Q2 25 | $211.4M | $384.4M | ||
| Q1 25 | $197.1M | $327.7M | ||
| Q4 24 | $190.6M | $333.0M | ||
| Q3 24 | $148.3M | $378.8M | ||
| Q2 24 | $138.0M | $390.1M |
净利润ANIPAPLE
| Q1 26 | — | $27.7M | ||
| Q4 25 | $27.5M | $29.6M | ||
| Q3 25 | $26.6M | $50.9M | ||
| Q2 25 | $8.5M | $63.6M | ||
| Q1 25 | $15.7M | $31.2M | ||
| Q4 24 | $-10.3M | $29.8M | ||
| Q3 24 | $-24.2M | $56.3M | ||
| Q2 24 | $-2.3M | $73.9M |
毛利率ANIPAPLE
| Q1 26 | — | — | ||
| Q4 25 | — | 37.2% | ||
| Q3 25 | — | 40.6% | ||
| Q2 25 | — | 42.6% | ||
| Q1 25 | — | 39.0% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 41.9% | ||
| Q2 24 | — | 44.6% |
营业利润率ANIPAPLE
| Q1 26 | — | 14.2% | ||
| Q4 25 | 14.1% | 15.2% | ||
| Q3 25 | 15.9% | 19.4% | ||
| Q2 25 | 6.6% | 22.1% | ||
| Q1 25 | 13.3% | 15.5% | ||
| Q4 24 | -2.3% | 15.0% | ||
| Q3 24 | -13.8% | 20.5% | ||
| Q2 24 | 3.7% | 24.0% |
净利率ANIPAPLE
| Q1 26 | — | 8.2% | ||
| Q4 25 | 11.1% | 9.1% | ||
| Q3 25 | 11.7% | 13.6% | ||
| Q2 25 | 4.0% | 16.6% | ||
| Q1 25 | 8.0% | 9.5% | ||
| Q4 24 | -5.4% | 9.0% | ||
| Q3 24 | -16.3% | 14.9% | ||
| Q2 24 | -1.7% | 19.0% |
每股收益（稀释后）ANIPAPLE
| Q1 26 | — | $0.12 | ||
| Q4 25 | $1.14 | $0.13 | ||
| Q3 25 | $1.13 | $0.21 | ||
| Q2 25 | $0.36 | $0.27 | ||
| Q1 25 | $0.69 | $0.13 | ||
| Q4 24 | $-0.45 | $0.13 | ||
| Q3 24 | $-1.27 | $0.23 | ||
| Q2 24 | $-0.14 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $7.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $3.1B |
| 总资产 | $1.4B | $4.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPAPLE
| Q1 26 | — | $7.8M | ||
| Q4 25 | $285.6M | $8.5M | ||
| Q3 25 | $262.6M | $50.3M | ||
| Q2 25 | $217.8M | $7.9M | ||
| Q1 25 | $149.8M | $14.9M | ||
| Q4 24 | $144.9M | $10.3M | ||
| Q3 24 | $145.0M | $6.1M | ||
| Q2 24 | $240.1M | $7.2M |
总债务ANIPAPLE
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B |
股东权益ANIPAPLE
| Q1 26 | — | $3.1B | ||
| Q4 25 | $540.7M | $3.1B | ||
| Q3 25 | $505.8M | $3.2B | ||
| Q2 25 | $436.8M | $3.2B | ||
| Q1 25 | $418.6M | $3.2B | ||
| Q4 24 | $403.7M | $3.3B | ||
| Q3 24 | $405.9M | $3.3B | ||
| Q2 24 | $455.8M | $3.3B |
总资产ANIPAPLE
| Q1 26 | — | $4.9B | ||
| Q4 25 | $1.4B | $4.9B | ||
| Q3 25 | $1.4B | $4.9B | ||
| Q2 25 | $1.3B | $4.9B | ||
| Q1 25 | $1.3B | $4.9B | ||
| Q4 24 | $1.3B | $5.0B | ||
| Q3 24 | $1.3B | $5.0B | ||
| Q2 24 | $920.8M | $5.1B |
负债/权益比ANIPAPLE
| Q1 26 | — | — | ||
| Q4 25 | — | 0.49× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | 0.46× | ||
| Q2 24 | — | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPAPLE
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $370.2M | ||
| Q3 25 | $44.1M | $126.4M | ||
| Q2 25 | $75.8M | $108.8M | ||
| Q1 25 | $35.0M | $49.1M | ||
| Q4 24 | $15.9M | $405.4M | ||
| Q3 24 | $12.5M | $128.2M | ||
| Q2 24 | $17.4M | $127.3M |
自由现金流ANIPAPLE
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $282.0M | ||
| Q3 25 | $38.0M | $109.0M | ||
| Q2 25 | $71.8M | $96.2M | ||
| Q1 25 | $32.5M | $29.5M | ||
| Q4 24 | $13.5M | $327.1M | ||
| Q3 24 | $7.7M | $113.1M | ||
| Q2 24 | $13.0M | $115.0M |
自由现金流率ANIPAPLE
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 86.4% | ||
| Q3 25 | 16.7% | 29.2% | ||
| Q2 25 | 34.0% | 25.0% | ||
| Q1 25 | 16.5% | 9.0% | ||
| Q4 24 | 7.1% | 98.2% | ||
| Q3 24 | 5.2% | 29.9% | ||
| Q2 24 | 9.4% | 29.5% |
资本支出强度ANIPAPLE
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 27.0% | ||
| Q3 25 | 2.7% | 4.7% | ||
| Q2 25 | 1.9% | 3.3% | ||
| Q1 25 | 1.3% | 6.0% | ||
| Q4 24 | 1.3% | 23.5% | ||
| Q3 24 | 3.2% | 4.0% | ||
| Q2 24 | 3.2% | 3.2% |
现金转化率ANIPAPLE
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 12.50× | ||
| Q3 25 | 1.66× | 2.49× | ||
| Q2 25 | 8.87× | 1.71× | ||
| Q1 25 | 2.23× | 1.57× | ||
| Q4 24 | — | 13.59× | ||
| Q3 24 | — | 2.28× | ||
| Q2 24 | — | 1.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
APLE
| Comparable Hotels Total Revenue | $336.9M | 100% |
| RevPAR (Comparable Hotels) | $114.6K | 0% |
